https://ClinicalTrials.gov/show/NCT06159725

Interventional - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment

Persistent Infection|Cystic Fibrosis - 18 Years and older   (Adult, Older Adult)

Drug: CMTX-101|Drug: Placebo

Number and % of participants experiencing adverse events following a single IV infusion of CMTX-101|Number and % of participants experiencing serious adverse events following a single IV infusion of CMTX-101|Assess the CMax - observed maximum plasma concentration determined by ELISA following a single IV infustion of CMTX-101|Assess the TMax - time to reach maximum concentration curve following a single IV infusion of CMTX-101|Assess the AUC0-∞ Area under the concentration time curve from zero to infinite time following a single IV infusion of CMTX-101|Assess the Terminal phase elimination rate determined by ELISA following a single IV infusion of CMTX-101|Assess the Terminal elimination half- determined by ELISA following a single IV infusion of CMTX-101|Assess the Apparent total body clearance (CL/F) determined by ELISA following a single IV infusion of CMTX-101|Assess the Apparent volume distribution (Vx/F) determined by ELISA following a single IV infustion of CMTX-101|Evaluate the immunogenicity of CMTX-101 as measured by anti-drug antibodies (ADA) determined by the electrochemiluminescence assay following a single IV infustion of CMTX-101|Assess the apparent reduction in pulmonary P. auriginosa burden as measured by quantitative microbial culture of sputum